<DOC>
	<DOC>NCT01352884</DOC>
	<brief_summary>This is a Phase 1, open-label, multi-center, first time in human study of AMP-224 in adult patients with cancer that is not responding to standard therapy. This study will be conducted in two stages consisting of a Dose-Escalation stage and an Expansion Stage.</brief_summary>
	<brief_title>Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Must be able to provide informed consent In DoseEscalation: Must have solid tumor malignancy or cutaneous Tcell lymphoma that has relapsed and is refractory to standard therapy, or for which no standard therapy exists In Expansion Phase: Must have melanoma or ovarian cancer that is histologically or cytologically confirmed Ovarian cancer patients must have recurrent of persistent nonmucinous disease, and must not have received more than 2 prior chemotherapeutic regimens Melanoma patients must have recurrent or persistent nonocular AJCC Stage IIIC or IV disease that is surgically incurable and unresectable Melanoma patients with documented BRAF mutation that is known to be responsive to BRAF inhibitors must have failed or be intolerant to such inhibitors Must have measurable disease Must be able to provide access to archival (DoseEscalation Phase) and/or fresh tumor tissue (DoseEscalation and Expansion Phases) at Screening prior to study entry Must by at least 18 years old Must have adequate organ function Prior cancer therapies must have completed at least 14 days or 5 halflives (whichever is longer) prior to first dose of AMP224 Prior treatment with an antiPD1 antibody therapy Known antibody response against prior antibody therapy or fusion protein therapeutics Major surgery within 4 weeks prior to first dose of AMP224 Prior allogeneic or autologous bone marrow or organ transplantation Known and/or a history or evidence of autoimmune disease except vitiligo, resolved childhood asthma and stable hypothyroidism Received an immunomodulatory drug within 2 weeks of first dose of AMP224 Active infections requiring antibiotics, physician monitoring, or recurrent fevers &gt;100.4 degrees fahrenheit associated with a clinical diagnosis of active infection Patients with cirrhosis Clinically significant cardiac or electrocardiogram abnormalities History or evidence of HIV Active viral disease (except when the viral infection is associated with the malignancy) Regular use of illicit drugs or a recent history of substance abuse Pregnant or breastfeeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Tumor</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Melanoma</keyword>
</DOC>